ERIS Lifesciences Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹892 Cr +12.6% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
EL

ERIS Lifesciences Ltd

Q4 FY26Pharmaceuticals & Biotechnology

ERIS Lifesciences Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹757Cr
+7.4% YoY
−6.2% QoQ
Net profit
₹279Cr
+173.5% YoY
+156% QoQ
Margin
36%
0 pp YoY
+1 pp QoQ

What the Q4 FY26 call signalled

1 of 3 strong

RevenueModerate growth
MarginMargins steady
CapexCapex planned
Price₹1,328
Market cap₹19.1K Cr
P/E29.1

The short version

International business: Latin America (LatAm) expected to grow faster in FY27 due to more new product approvals; Africa, Asia, and LatAm remain key geographies with stable mix (~30% Africa, 30% Asia, 25% LatAm). Eris Lifesciences expects DBF revenue growth at 1.3x of covered market growth in FY27 with DBF EBITDA margin steady at ~37%, and higher margin in H2 than H1.

From ERIS Lifesciences Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Moderate growth
  • International business: Latin America (LatAm) expected to grow faster in FY27 due to more new product approvals; Africa, Asia, and LatAm remain key geographies with stable mix (~30% Africa, 30% Asia, 25% LatAm).
  • EU CDMO: No base case revenue expected in FY27; any revenue would be upside; major revenues anticipated from FY28 onwards.
  • Domestic Formulations (DBF): Overall DBF growth around 11-12%; insulin and derma therapies already outperforming; cardiovascular (CVD) segment catching up; other oral anti-diabetic (OAD) therapies expected to require more time to catch up.

2 more points from ERIS Lifesciences Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what ERIS Lifesciences Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • INR 160-180 crores invested in developing a large biotech play (DS facility).
  • INR 250 crores invested in Bhopal fill and finish site, which is expected to improve margins and open new markets once operational.
  • A map facility set up at Bhopal, considered future-focused but delayed by 1 to 1.5 years.
  • Additional plant investment for Swiss Parenterals with commissioning expected in April, doubling current parenteral capacity.
  • No major CapEx planned for remediation related to EU GMP inspection; mainly procedural and training-related improvements.

2 more points from ERIS Lifesciences Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what ERIS Lifesciences Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Some related insights can be summarized: - The EU CDMO business has no impact on the existing order book; key contracts continue as planned. - A product commercialization expected in Q1 got delayed due to regulatory issues, affecting revenue timing but not the order book. - International business debtor days have reduced, indicating improved collections, which could positively impact order execution.

2 more points from ERIS Lifesciences Ltd's call on order book

Create a free account to keep reading this call

ERIS Lifesciences Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

ERIS Lifesciences Ltd Q4 FY26 results — key figures

ERIS Lifesciences Ltd Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue757705+7.4%807-6.2%
Operating profit (EBITDA)272252+7.9%282-3.5%
Operating margin36%36%0 pp35%+1 pp
Profit before tax159129+23.3%145+9.7%
Net profit (PAT)279102+173.5%109+156%
EPS (₹)20.336.89+195.1%7.32+177.7%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹892 Cr, net profit ₹187 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

ERIS Lifesciences Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were ERIS Lifesciences Ltd Q4 FY26 results?

International business: Latin America (LatAm) expected to grow faster in FY27 due to more new product approvals; Africa, Asia, and LatAm remain key geographies with stable mix (~30% Africa, 30% Asia, 25% LatAm). Eris Lifesciences expects DBF revenue growth at 1.3x of covered market growth in FY27 with DBF EBITDA margin steady at ~37%, and higher margin in H2 than H1.

What is ERIS Lifesciences Ltd share price analysis?

ERIS Lifesciences Ltd currently shows a below-average growth signal. The stock trades at a P/E of 29.1 with a market cap of ₹19,057 Cr. Investors should review the full earnings analysis for detailed insights.

Is ERIS Lifesciences Ltd planning capital expenditure?

INR 160-180 crores invested in developing a large biotech play (DS facility).

Keep ERIS Lifesciences Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.